Videos and webcasts available on demand
-
Guiding N1 treatment decisions after RxPONDER
Prof. Catherine Kelly from the Trinity St James Cancer Institute in Dublin presents the RxPONDER results.
Guiding N1 treatment decisions after RxPONDER
Prof. Catherine Kelly from the Trinity St James Cancer Institute in Dublin presents the RxPONDER results. -
Initial RxPONDER results in clinical practice: What will change?
Prof. Stephen Chia from the University of British Columbia, Canada and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial RxPONDER results presented at SABCS 2020 and what impact this has on the clinical practice.
Initial RxPONDER results in clinical practice: What will change?
Prof. Stephen Chia from the University of British Columbia, Canada and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial... -
Clinical practice revisited: Improving chemotherapy treatment decisions in early-stage breast cancer
Prof. Hartkopf from the University of Tuebingen talks about the evidence from his clinical practice and which parameters guide treatment decisions in early-stage breast cancer. Prof. Thill form Agaplesion Markus Hospital discusses real-world evidence from the REMAR study and how treatment decisions are optimized with multigene testing.
Clinical practice revisited: Improving chemotherapy treatment decisions in early-stage breast cancer
Prof. Hartkopf from the University of Tuebingen talks about the evidence from his clinical practice and which parameters guide treatment decisions in... -
The Oncotype DX Breast Recurrence Score assay in clinical practice
Prof. Maccon Keane from the Saolta University Health care Group at the University Hospital Galway in Ireland discusses the Oncotype DX Breast Recurrence Score®assay evidence and in particular, the TAILORx landmark trial data.
The Oncotype DX Breast Recurrence Score assay in clinical practice
Prof. Maccon Keane from the Saolta University Health care Group at the University Hospital Galway in Ireland discusses the Oncotype DX Breast ... -
Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy
Watch an expert panel at the 2019 St. Gallen International Breast Cancer Conference discuss evidence on how to guide adjuvant chemotherapy treatment decisions in HER2-, HR+, early-stage breast cancer patients.
Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy
Watch an expert panel at the 2019 St. Gallen International Breast Cancer Conference discuss evidence on how to guide adjuvant chemotherapy treatment...